Why Streamlining Support Is Key to Long-Term Adherence

Key Takeaways

• EHR‑embedded tools deliver support exactly when a prescription is written
• Point‑of‑care integration reduces patient drop‑off before first dose
• Simplified digital workflows cut administrative burden for providers
• Higher adherence translates to lower total cost of care for payers

Pulse Analysis

The specialty drug market has long grappled with a paradox: high clinical efficacy paired with low real‑world adherence. While manufacturers invest heavily in hub services and AI‑powered outreach, many patients still fall through the cracks during the critical transition from prescription to first administration. Embedding support directly into electronic health‑record platforms addresses this gap by meeting clinicians where they already work, eliminating the need for separate portals or phone calls. This seamless handoff not only accelerates enrollment but also provides instant eligibility checks, reducing delays that can erode patient confidence.

From a business perspective, the financial stakes are significant. Specialty therapies often exceed $100,000 per year, and non‑adherence can waste up to 30% of that investment. By streamlining support, manufacturers can improve medication possession ratios, which in turn enhances outcomes and strengthens payer relationships. Moreover, integrated digital tools generate richer data streams, enabling real‑time analytics on patient behavior and allowing rapid adjustments to support programs. This data‑driven approach aligns with the broader industry shift toward value‑based care, where reimbursement increasingly ties to measurable results.

Looking ahead, the evolution of support models will likely converge with broader health‑tech trends such as interoperable APIs and patient‑centric portals. Companies that prioritize clean, interoperable solutions will gain a competitive edge, attracting providers who demand efficiency and patients who seek convenience. As regulatory bodies continue to emphasize transparency and outcomes, the ability to demonstrate improved adherence through integrated support will become a key differentiator in the specialty pharmaceutical landscape.